Amendment No. 1 to Engagement Letter between DelMar Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC (February 21, 2017)
DelMar Pharmaceuticals, Inc. and H.C. Wainwright & Co., LLC have agreed to extend the term of their original engagement letter, dated January 24, 2017, by an additional 30 days. All other terms and conditions of the original agreement remain unchanged and in effect. This amendment is signed by authorized representatives of both parties.
Exhibit 10.3
February 21, 2017
STRICTLY CONFIDENTIAL
Jeffrey Bacha
Chairman & CEO
DelMar Pharmaceuticals, Inc.
Suite 720 - 999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5
Dear Mr. Bacha:
This letter shall serve as an amendment (the “Amendment”) to that certain engagement letter (the “Original Letter”), dated as of January 24, 2017, by and between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Defined terms used herein and not otherwise defined herein shall have the meaning ascribed to them in the Original Letter.
Wainwritght and the Company hereby mutually agree to extend the Term of the Original Letter pursuant to Section B. for an additional 30 days.
Except as modified by this letter, the terms, provisions and requirements of the Original Letter shall remain the same and in full force and effect in accordance with the terms and provisions thereof.
| Very truly yours, | ||
| H.C. WAINWRIGHT & CO., LLC | ||
| By: | /s/ Edward D. Silvera | |
| Name: Edward D. Silvera | ||
| Title: COO | ||
| Accepted and Agreed: | ||
DELMAR PHARMACEUTICALS, INC. | ||
| By: | /s/ Jeffrey A. Bacha | |
| Name: | Jeffrey A. Bacha | |
| Title | Chairman & CEO | |
